Pharmacology of immunosuppressive drugs

被引:11
作者
Olyaei, AJ [1 ]
de Mattos, AM [1 ]
Bennett, WM [1 ]
机构
[1] Oregon Hlth Sci Univ, Div Nephrol Hypertens & Clin Pharmacol, Portland, OR 97201 USA
来源
DRUGS OF TODAY | 1998年 / 34卷 / 05期
关键词
D O I
10.1358/dot.1998.34.5.485245
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immunosuppressive therapy of solid organ transplantation has become more potent, effective and selective since the results of earlier use of prednisone and azathioprine post renal transplantation. Calcineurin inhibitors and mycophenolate mofetil have been important additions to the effective antirejection armamentarium. Today, ciclosporin, tacrolimus, azathioprine, mycophenolate and prednisone are all effective immunosuppressive agents and are the cornerstone of immunosuppressive protocols used posttransplant. However, the use of these agents is hindered by a 20% rate of rejection, lack of selectivity and-a high rate of major adverse drug reactions which ultimately lead to a decrease in patient and graft survival. A number of clinical trials are underway to compare efficacy, safety and tolerability of different combination protocols to improve patient and allograft survival and decrease adverse drug reactions. Clinical knowledge of the pharmacology, pharmacokinetics, pharmacodynamics, adverse drug reactions and therapeutic drug monitoring of antirejection agents is essential for designing an effective immunosuppressive protocol for individual solid organ transplant recipients. The clinical application of pharmacotherapeutic principles into the clinical practice will improve both long-term patient and allograft survival while minimizing systemic toxicity of immunosuppressive drugs. (C) 1998 Prous Science. All rights reserved.
引用
收藏
页码:463 / 479
页数:17
相关论文
共 168 条
[81]  
LAKE KD, 1991, PHARMACOTHERAPY, V11, pS110
[82]   MECHANISM OF LYMPHOCYTE-T ACTIVATION BY OKT3 ANTIBODIES - A GENERAL-MODEL FOR T-CELL INDUCTION [J].
LANDEGREN, U ;
ANDERSSON, J ;
WIGZELL, H .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1984, 14 (04) :325-328
[83]   AZATHIOPRINE METABOLISM IN KIDNEY-TRANSPLANT RECIPIENTS [J].
LENNARD, L ;
BROWN, CB ;
FOX, M ;
MADDOCKS, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :693-700
[84]   PROGRESSION AND REMISSION OF RENAL-DISEASE IN THE LUPUS NEPHRITIS COLLABORATIVE STUDY - RESULTS OF TREATMENT WITH PREDNISONE AND SHORT-TERM ORAL CYCLOPHOSPHAMIDE [J].
LEVEY, AS ;
LAN, SP ;
CORWIN, HL ;
KASINATH, BS ;
LACHIN, J ;
NEILSON, EG ;
HUNSICKER, LG ;
LEWIS, EJ .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (02) :114-123
[85]   GLOMERULONEPHRITIS CAUSED BY CHRONIC HEPATITIS-B VIRUS-INFECTION - TREATMENT WITH RECOMBINANT HUMAN ALPHA-INTERFERON [J].
LISKERMELMAN, M ;
WEBB, D ;
DIBISCEGLIE, AM ;
KASSIANIDES, C ;
MARTIN, P ;
RUSTGI, V ;
WAGGONER, JG ;
PARK, Y ;
HOOFNAGLE, JH .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (06) :479-483
[86]  
LU CY, 1993, J AM SOC NEPHROL, V4, P1239
[87]   A PROSPECTIVE RANDOMIZED STUDY OF PROPHYLACTIC OKT3 VERSUS EQUINE ANTITHYMOCYTE GLOBULIN AFTER HEART-TRANSPLANTATION - INCREASED MORBIDITY WITH OKT3 [J].
MACDONALD, PS ;
MUNDY, J ;
KEOGH, AM ;
CHANG, VP ;
SPRATT, PM .
TRANSPLANTATION, 1993, 55 (01) :110-116
[88]  
Malinow L, 1996, CLIN TRANSPLANT, V10, P237
[89]  
MIESFELD RL, 1990, AM REV RESPIR DIS, V141, pS11
[90]  
MIHATSCH MJ, 1994, CLIN NEPHROL, V41, P23